i2o: FDA advisory committee voted unanimously to reject an appeal for Intarcia Therapeutics' Type 2 diabetes drug-device combination treatment, citing continued safety concerns.
An FDA advisory committee voted unanimously to reject an appeal for Intarcia Therapeutics' Type 2 diabetes drug-device combination treatment, citing continued safety concerns
Read full article »
i2o is a Massachusetts-based biotechnology company that researches and develops oral peptide and protein therapies for the treatment of cardiometabolic diseases.
Read more